Skip to main content
. 2021 Aug 18;20:169. doi: 10.1186/s12933-021-01362-y

Fig. 1.

Fig. 1

Participants flow chart. GLA glucose lowering agent; SGLT2i Sodium/glucose cotransporter-2 inhibitors; ESKD end stage kidney disease; MHS Maccabi Health Systems; T1D type 1 diabetes; eGFR estimated glomerular filtration rate